Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Zhang S, Wang F, Zhang Z. Current advances in the elimination of hepatitis B in China by 2030. Front Med. 2017;11:490–501.

Article  PubMed  Google Scholar 

Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64:1289–95.

Article  CAS  PubMed  Google Scholar 

Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer. 2020;147:317–30.

Article  CAS  PubMed  Google Scholar 

Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16:57–73.

Article  PubMed  Google Scholar 

White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342–59.e2.

Article  PubMed  PubMed Central  Google Scholar 

Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications—what the non-specialist needs to know. Diabetes Obes Metab. 2022;24:3–14.

Article  PubMed  Google Scholar 

Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47–64.

Article  PubMed  Google Scholar 

Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.

Article  PubMed  Google Scholar 

Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904.

Article  PubMed  Google Scholar 

Farrell GC, Chitturi S, Lau GK, Sollano JD, Asia-Pacific Working Party on N. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22:775–7.

Article  PubMed  Google Scholar 

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–9.

Article  PubMed  Google Scholar 

Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014.e1.

Article  CAS  PubMed  Google Scholar 

Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab. 2022;107:88–97.

Article  PubMed  Google Scholar 

Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75:1476–84.

Article  PubMed  Google Scholar 

Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38:251–60.

Article  CAS  PubMed  Google Scholar 

Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28:150–63.

Article  PubMed  Google Scholar 

Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107:2691–700.

Article  PubMed  Google Scholar 

Pan F, Cao S, Li XL, Jia YN, Wang RL, He Q, et al. The model for end-stage liver disease score and the follow-up period can cause the shift of circulating lymphocyte subsets in liver transplant recipients. Front Med (Lausanne). 2021;8:779443.

Article  PubMed  Google Scholar 

Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl. 2001;7:S13–21.

Article  CAS  PubMed  Google Scholar 

Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010;53:199–206.

Article  PubMed  Google Scholar 

Kurdi A, Martinet W, De Meyer GRY. mTOR inhibition and cardiovascular diseases: dyslipidemia and atherosclerosis. Transplantation. 2018;102:S44–S6.

Article  CAS  PubMed  Google Scholar 

Jindal RM, Sidner RA, Milgrom ML. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf. 1997;16:242–57.

Article  CAS  PubMed  Google Scholar 

Xu WL, Wang RL, Liu Z, Wu Q, Li XL, He Q, et al. Granzyme B-producing B cells function as a feedback loop for T helper cells in liver transplant recipients with acute rejection. Inflammation. 2021;44:2270–8.

Article  CAS  PubMed  Google Scholar 

Zhu JQ, Wang J, Li XL, Xu WL, Lv SC, Zhao X, et al. A combination of the percentages of IFN-gamma(+)CD4(+)T cells and granzyme B(+)CD19(+)B cells is associated with acute hepatic rejection: a case control study. J Transl Med. 2021;19:187.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bechtold M, Palmer J, Valtos J, Iasiello C, Sowers J. Metabolic syndrome in the elderly. Curr Diab Rep. 2006;6:64–71.

Article  CAS  PubMed  Google Scholar 

Jimenez-Perez M, Gonzalez-Grande R, Omonte Guzman E, Amo Trillo V, Rodrigo Lopez JM. Metabolic complications in liver transplant recipients. World J Gastroenterol. 2016;22:6416–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 2004;135:48–58.

Article  PubMed  Google Scholar 

Wang MD, Tang SC, Li C, Sun LY, Xu X, Liang YJ, et al. Association of concurrent metabolic syndrome with long-term oncological prognosis following liver resection for hepatocellular carcinoma among patients with Chronic Hepatitis B virus infection: a multicenter study of 1753 patients. Ann Surg Oncol. 2023;30:346–58.

Article  PubMed  Google Scholar 

Dai J, Zhu X, Shen J, Zhang Y, Xie F, Yu Y, et al. The effect of metabolic syndrome on the outcome of Hepatitis B-associated hepatocellular carcinoma patients after hepatectomy: a multicenter study. Front Oncol. 2022;12:811084.

Article  PubMed  PubMed Central  Google Scholar 

Tabrizian P, Holzner ML, Mehta N, Halazun K, Agopian VG, Yao F, et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 2022;157:779–88.

PubMed  PubMed Central  Google Scholar 

Vitale A, Peck-Radosavljevic M, Giannini EG, Vibert E, Sieghart W, Van Poucke S, et al. Personalized treatment of patients with very early hepatocellular carcinoma. J Hepatol. 2017;66:412–23.

Article  PubMed  Google Scholar 

Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, et al. Validation of a risk estimation of tumor recurrence after transplant (retreat) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017;3:493–500.

Article  PubMed  PubMed Central  Google Scholar 

Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, et al. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors. Ann Surg. 2020;272:855–62.

Article  PubMed  Google Scholar 

Rodriguez-Peralvarez M, Colmenero J, Gonzalez A, Gastaca M, Curell A, Caballero-Marcos A, et al. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation. Am J Transpl. 2022;22:1671–82.

Article  CAS  Google Scholar 

Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Prognostic impact of MAFLD following surgical resection of Hepatitis B virus-related hepatocellular carcinoma: a nationwide cohort study. Cancers (Basel). 2022;14:5002.

Article  PubMed  Google Scholar 

Lin YP, Wang PM, Chuang CH, Yong CC, Liu YW, Huang PY, et al. Metabolic risks are increasing in non-B non-C early-stage hepatocellular carcinoma: a 10-year follow-up study. Front Oncol. 2022;12:816472.

Article  CAS  PubMed  PubMed Central